Nuclear medicine is an imaging technique for diagnostic or therapeutic purposes, used for certain pathologies by intravenous administration of radioactive tracers.
Nuclear Medicine is a molecular and functional imaging and treatment technique. It applies to all organs and / or system diseases and can be used for both adults and children.
Nuclear medicine investigations consist in administering, most often by intravenous injection, a substance labelled with a radioactive isotope. The substance to be administered is chosen according to the organ or system to be explored. Nuclear medicine diagnostic tests (scintigraphy) are carried out using detection devices (gamma camera, SPECT, PET) coupled or not to a CT (SPECT / CT, PET / CT) in hybrid imaging. This technique allows the evaluation of the activity of a disease in correlation with the anatomical imaging.
Scintigraphy, SPECT and SPECT/CT carried out in our Institute:
- Bone scan (oncological assessment, unexplained bone pain, mechanical or septic loosening of the prosthesis,...)
- Myocardial perfusion scintigraphy
- Lymphoscintigraphy and sentinel lymph node (melanoma, breast cancer, ...)
- Renal scintigraphy with separate renal function measurement, post-renal disease assessment, reno-vascular involvement (paediatric and adult)
- Pulmonary scintigraphy for the diagnosis of embolism, thrombo-embolic disease, preoperative functional evaluation
- Thyroid scintigraphy for the differential diagnosis of hyperthyroidism, evaluation before treatment
- Parathyroid scintigraphy for adenoma localisation
- Gastrointestinal evaluation (oesophageal transit, reflux, gastric emptying, Meckel diverticulum)
- Pheochromocytomas, neuroendocrine tumours (I-123-mIBG, In-111-Octreoscan)
PET/CT studies carried out in our Institute:
- F-18 FDG for accurate staging of the disease, evaluation of response to treatment
- F-18 choline or Ga-68 PSMA in case of biochemical recurrence of prostate cancer
- F-18 FET for primary brain tumour recurrence
Targeted radionuclide therapy carried out in our Institute:
- Xofigo® in patients with bone metastases of prostate cancer
- Iodine-131 for hyperthyroidism